AVITA Medical, Inc.
About AVITA Medical, Inc.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $71.6M
- Net income
- -$48.6M
- Total assets
- $56.4M
- Market cap
- $128.6M
- Gross margin
- 82.1%
- Operating margin
- -59.4%
- Net margin
- -67.8%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $71.6M
- Cost of revenue
- $12.8M
- Gross profit
- $58.8M
- Operating expenses
- $101.3M
- Operating income
- -$42.5M
- Income tax
- $11.0K
- Net income
- -$48.6M
- EPS (basic)
- $-1.74
- EPS (diluted)
- $-1.74
Balance sheet
- Total assets
- $56.4M
- Current assets
- $35.5M
- Total liabilities
- $73.0M
- Current liabilities
- $62.7M
- Shareholders’ equity
- -$16.6M
Cash flow
- Operating cash flow
- -$31.2M
- Investing cash flow
- $12.5M
- Financing cash flow
- $14.9M
- Net cash flow
- -$3.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $128.6M
- EPS (diluted)
- $-1.74
- Shares outstanding
- 30.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 8, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $48.6M in FY2025.
- Revenue grew 145% from FY2021 to FY2025.
- Gross margin of 82.1%, net margin -67.8%.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AVITA Medical, Inc..
Write a review
News about AVITA Medical, Inc.
News & sentiment via Polygon.io
